- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | Rapid Micro Biosystems stellt auf KeyBanc-Forum strategische Wachstumspläne vor | 1 | Investing.com Deutsch | ||
| 12.03. | RAPID MICRO BIOSYSTEMS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | RAPID MICRO BIOSYSTEMS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.03. | Rapid Micro Biosystems outlines $37M-$41M 2026 revenue target amid record system placements and margin expansion drive | 1 | Seeking Alpha | ||
| 12.03. | Rapid Micro Biosystems: Starker Umsatz, aber höherer Verlust im Q4 2025 - Aktie bricht vorbörslich ein | 2 | Investing.com Deutsch | ||
| 12.03. | Rapid Micro Biosystems reports mixed Q4 results; introduces FY26 outlook | 3 | Seeking Alpha | ||
| RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
| 12.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct Platform | 974 | GlobeNewswire (Europe) | LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation... ► Artikel lesen | |
| 10.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum | 2 | GlobeNewswire (USA) | ||
| 24.02. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 | 1 | GlobeNewswire (USA) | ||
| 12.02. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 14.01. | After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones | 586 | AFX News | BEIJING (dpa-AFX) - Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical... ► Artikel lesen | |
| 13.01. | Rapid Micro Biosystems reports Q4 results | 1 | Seeking Alpha | ||
| 13.01. | Rapid Micro Biosystems reports 37% revenue growth in Q4 2025 | 4 | Investing.com | ||
| 13.01. | Rapid Micro Biosystems reports preliminary fourth quarter revenue | 2 | Seeking Alpha | ||
| 13.01. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue | 1.078 | GlobeNewswire (Europe) | Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period.Received record multi-system order in the fourth... ► Artikel lesen | |
| 13.01. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 11.11.25 | Rapid Micro Biosystems: GrowthDirect-Plattform im Fokus der Wachstumsstrategie | 2 | Investing.com Deutsch | ||
| 07.11.25 | Rapid Micro Biosystems raises 2025 revenue guidance to at least $33M amid record multi-system order and accelerating margin improvement | 2 | Seeking Alpha | ||
| 07.11.25 | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.11.25 | RAPID MICRO BIOSYSTEMS, INC. Q3 Loss Misses Estimates | 1 | RTTNews |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 4,750 | 0,00 % | What's Going On With bioAffinity Stock Thursday? | ||
| APOGEE THERAPEUTICS | 79,16 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CG ONCOLOGY | 64,92 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,750 | 0,00 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen | |
| QIAGEN | 34,325 | +0,23 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ERASCA | 14,310 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| ARCELLX | 114,61 | 0,00 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,570 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| PRAXIS PRECISION MEDICINES | 293,87 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 36,500 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,400 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| BIONTECH | 76,15 | -1,23 % | Aktuelle Aktien-Empfehlungen: Shell, BioNTech, Hypoport | Die aktuelle Analystenlandschaft zeigt sich weiterhin konstruktiv gegenüber einer Reihe europäischer und internationaler Titel. Mehrere Research-Häuser bestätigen ihre Kaufempfehlungen und heben ihre... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 49,080 | +1,15 % | Citizens reiterates Structure Therapeutics stock rating on weight loss data | ||
| VALNEVA | 2,956 | -34,60 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| ALUMIS | 23,370 | 0,00 % | Alumis Inc.: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements | - Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis... ► Artikel lesen |
RAPID MICRO BIOSYSTEMS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPID MICRO BIOSYSTEMS INC finden Sie auf Wallstreet Online.